Amphetamine Use Disorders
Conditions
Keywords
Amphetamine-type stimulants, temporal interference stimulation
Brief summary
Targeted temporal interference stimulation (tTIS) of the caudate nucleus can modulate the abnormal electrophysiological activity in individuals with methamphetamine use disorder (MUD), thereby improving their impaired reward-learning behaviors and reducing drug craving.
Detailed description
This project will recruit MUD patients. A 5-day intervention protocol of real or sham tTIS targeting the caudate nucleus will be employed. Before and after intervention, drug craving anddrug use and other questionnaire as well as stop-signal tasks, and reward-learning tasks will be used to evaluate its therapeutic efficacy on clinical craving and the underlying neural mechanisms.
Interventions
DEVICETemporal Interference Stimulation
The stimulation duration are 30 minutes per session, administered twice daily for 5 consecutive days.
DEVICEShame
The stimulation parameters-including frequency, current intensity, and duration-are identical to those in the active group. Sham stimulation used the same montage and ramp procedures but delivered stimulation for only 1 minute per session before the stimulator was turned off.
Sponsors
Shanghai Mental Health Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Individuals aged between 18 and 55 years, irrespective of gender, having completed a minimum of 6 years of education and capable of effectively cooperating in questionnaire evaluations. * Meet the diagnostic criteria set forth by the DSM-V concerning the amphetamine-type substance addiction. * A history of utilizing amphetamine-type substances for a duration not less than one year, with a frequency of use being at least once per week. * Consent to actively cooperate in the completion of subsequent follow-up assessments.
Exclusion criteria
* Severe cognitive functional impairments manifested through a history of head trauma, cerebrovascular diseases, epilepsy, etc., or usage of cognitive enhancement drugs in the past 6 months; an intellectual disability with an IQ score less than 70. * A diagnosis of schizophrenia or other severe mental illnesses as per the DSM-5 criteria. * Abuse or dependence on other psychoactive substances (excluding nicotine) within the past 5 years. * Severe organic diseases that might compromise study participation. * Contraindications to cTBS, such as a history of epileptic seizures or the presence of metallic implants in proximity to the head.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of Craving | baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment | Visual Analog Scale, range0-100 point. the higher the score, the more one wants drugs. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Drug Use | baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment | OCDUSE scale |
| impulsivity | baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment | This study employed the BIS-11 Impulsiveness Scale |
| Changes in Reward Learning | baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment | Reward LearningTask |
| Decision-making Preferences and Delay of Gratification | baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment | delay discounting task |
| sensitivity to reward and punishment | baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment | the Sensitivity to Punishment and Sensitivity to Reward Questionnaire, the Cognitive Flexibility Scale, the Behavioral Inhibition/Activation System Scale |
| emotional states | baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment | the BDI Depression Inventory |
| emotional state | baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment | the BAI Anxiety Inventory |
| sleep quality | baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment, 13 weeks after treatment | the PSQI Sleep Quality Index |
| EEG | baseline, 1 day after treatment, 7 day after treatment, 2 weeks after treatment | source power of each frequency band |
Countries
China
Contacts
STUDY_CHAIRMin Zhao, PhD
Shanghai Mental Health Center
Outcome results
None listed